The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral Leishmaniasis.
about
Recent developments and future prospects in the treatment of visceral leishmaniasisNitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospectsRecent developments in drug discovery for leishmaniasis and human African trypanosomiasisTrypanothione reductase: a target protein for a combined in vitro and in silico screening approachDevelopment and Validation of a Novel Leishmania donovani Screening Cascade for High-Throughput Screening Using a Novel Axenic Assay with High Predictivity of Leishmanicidal Intracellular Activity.Activation of Bicyclic Nitro-drugs by a Novel Nitroreductase (NTR2) in LeishmaniaEvaluating aziridinyl nitrobenzamide compounds as leishmanicidal prodrugsNitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis.Discovery of Indoline-2-carboxamide Derivatives as a New Class of Brain-Penetrant Inhibitors of Trypanosoma brucei.The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasisInvestigational drugs for visceral leishmaniasis.Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art.Snapshot Profiling of the Antileishmanial Potency of Lead Compounds and Drug Candidates against Intracellular Leishmania donovani Amastigotes, with a Focus on Human-Derived Host Cells.Nitroarenes as Antitubercular Agents: Stereoelectronic Modulation to Mitigate Mutagenicity.Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.A role for trypanosomatid aldo-keto reductases in methylglyoxal, prostaglandin and isoprostane metabolismAntitrypanosomal 8-Hydroxy-Naphthyridines Are Chelators of Divalent Transition Metals
P2860
Q26740563-180CE864-69B9-4B8F-A35F-3CBDC37A6F36Q26863285-67DE5694-9723-45E7-8011-F1CB161165B3Q27011766-63F81259-EEE3-4CFA-86C8-7AE8FC3D9DE9Q28547882-32EB09D4-CCB3-402A-A77D-7BA3745BA72BQ28548536-16568DBE-5E77-4D93-A13B-26AD7C42F21EQ28553178-10C26671-4ED2-4776-9521-02F5D269B001Q35027309-99CBE840-14E2-47F6-BDF9-694E22BF48B5Q35412114-7046B16C-222F-4FA9-A11F-2D338EDE0CDBQ35791902-1031D7C1-5CC4-43D3-9937-EEF90AD6F3E5Q36932080-909486A3-2993-406C-AC4D-C937C2D4904BQ38269581-E38681A7-F0EC-49B6-8BB1-8568C81A6799Q38939544-5D44F56E-02ED-45FC-92A8-D7F80C68247AQ39144812-D2919B69-0EA7-48E1-B50B-BF452E9A849BQ40838217-F51BD65D-8DE4-42D6-9B8A-C79310DC745CQ51730628-BDF06041-6CAF-4106-A6D9-FFD44E66052FQ58694598-8B71E06D-56EA-46AF-9A8D-BB76B1D65844Q58850065-88FBD888-6695-4A54-A2A1-A93F53871FC5
P2860
The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral Leishmaniasis.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The R enantiomer of the antitu ...... nt for visceral Leishmaniasis.
@ast
The R enantiomer of the antitu ...... nt for visceral Leishmaniasis.
@en
type
label
The R enantiomer of the antitu ...... nt for visceral Leishmaniasis.
@ast
The R enantiomer of the antitu ...... nt for visceral Leishmaniasis.
@en
prefLabel
The R enantiomer of the antitu ...... nt for visceral Leishmaniasis.
@ast
The R enantiomer of the antitu ...... nt for visceral Leishmaniasis.
@en
P2093
P2860
P50
P356
P1476
The R enantiomer of the antitu ...... nt for visceral Leishmaniasis.
@en
P2093
Frederick R C Simeons
Kevin D Read
Laste Stojanovski
Maria Osuna-Cabello
Meghan R Perry
Stephen Patterson
Suzanne Norval
P2860
P304
P356
10.1128/AAC.00722-13
P407
P577
2013-07-15T00:00:00Z